BI 765063
Sponsors
OSE Immunotherapeutics, Boehringer Ingelheim
Conditions
Carcinoma, Squamous Cell of Head and Neck (HNSCC)Colorectal CancerHead and Neck Squamous Cell Carcinoma (HNSCC)MelanomaNon-small Cell Lung Cancer (NSCLC)Solid Tumor, AdultSolid Tumors
Phase 1
A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
CompletedNCT03990233
Start: 2019-04-16End: 2025-04-30Updated: 2025-06-26
A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)
CompletedNCT04653142
Start: 2020-12-15End: 2022-04-20Updated: 2022-05-10
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Active, not recruitingNCT05068102
Start: 2022-03-03End: 2026-05-31Updated: 2026-02-18
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
Active, not recruitingNCT05249426
Start: 2022-04-12End: 2026-07-31Updated: 2026-01-21
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
TerminatedNCT05446129
Start: 2022-09-27End: 2023-11-08Updated: 2025-03-13